---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119077"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:13:19.178580+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports Q3 2024 net loss of $2.3M; receives $4M NIH grants

## Summary
- Cash and cash equivalents of $9.0M as of Sept 30, 2024; expects to fund operations into October 2025.
- Net loss from continuing operations improved to $2.3M (Q3 2024) from $3.0M (Q3 2023).
- R&D expenses rose to $3.5M (Q3 2024) vs $2.0M (Q3 2023) due to increased clinical trial activity.
- Received two $2M SBIR grants from NIH ($4M total) to support MT-601 trials in lymphoma and pancreatic cancer.
- Phase 1 APOLLO study of MT-601 in lymphoma continues enrolling; expects preliminary data by end of 2024.

## SEC filing metadata
- accession: 0001104659-24-119077
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/0001104659-24-119077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/tm2421372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119077
- JSON: https://secwatch.observer/filing/0001104659-24-119077.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.